Norges Bank Purchases Shares of 5,653,304 Edison International $EIX
Norges Bank has acquired a new stake of 5,653,304 shares in Edison International (NYSE:EIX) during the fourth quarter, valued at approximately $339 million. This purchase makes Norges Bank the owner of 1.47% of Edison International's stock. Other institutional investors have also adjusted their positions in EIX, and the company recently reported earnings that beat consensus estimates, with revenue slightly below expectations.
2,019,197 Shares in Raymond James Financial, Inc. $RJF Purchased by Norges Bank
Norges Bank recently acquired a new position in Raymond James Financial, Inc. (NYSE:RJF), purchasing over 2 million shares valued at approximately $324.26 million in the 4th quarter. This acquisition makes Norges Bank a significant institutional holder with about 1.02% of the company's stock. Other institutional investors like JPMorgan Chase & Co. and First Trust Advisors LP also increased their holdings, contributing to 83.83% institutional ownership of Raymond James Financial.
Fair Isaac Corporation $FICO Shares Sold by Nomura Asset Management Co. Ltd.
Nomura Asset Management Co. Ltd. significantly reduced its stake in Fair Isaac Corporation ($FICO) by 45% in the fourth quarter, selling 13,914 shares. Despite this, institutional ownership remains high at 85.75%, with several other firms increasing their positions. Fair Isaac recently reported strong quarterly earnings, surpassing EPS and revenue expectations, and authorized a $1.5 billion stock buyback program.
Illinois Tool Works Inc. $ITW Shares Acquired by MUFG Securities EMEA plc
MUFG Securities EMEA plc significantly increased its stake in Illinois Tool Works Inc. by 113.2% in the fourth quarter, holding 10,822 shares valued at approximately $2.67 million. This comes as Illinois Tool Works reported strong Q1 earnings, surpassing expectations with $2.66 per share and raising its full-year EPS outlook to $11.10-$11.50 for fiscal year 2026. Despite a quarterly dividend declaration of $1.61 per share, analysts maintain a cautious "Reduce" consensus rating with an average price target of $271.92, indicating potential headwinds or conservative outlooks for the industrial products company.
MUFG Securities EMEA plc Raises Position in NXP Semiconductors N.V. $NXPI
MUFG Securities EMEA plc significantly increased its stake in NXP Semiconductors N.V. by 113.8% in the fourth quarter, now holding 10,318 shares valued at approximately $2.24 million. This increased position follows NXP's strong quarterly results, which surpassed analyst expectations with an EPS of $3.05 and revenue of $3.18 billion. Analysts maintain a "Moderate Buy" consensus for NXP, with an average price target of $294.25, and several firms have recently raised their price objectives.
How to watch Moderna's Goldman Sachs healthcare talk on June 9
Moderna (Nasdaq: MRNA) announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, at 3:20 p.m. ET. Investors can access a live webcast and a 30-day replay of the presentation through the Investors section of Moderna's website. The company is a pioneer in mRNA medicine, focusing on developing vaccines and therapeutics for various diseases.
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab for advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signals of anti-tumor activity, with some patients achieving stable disease and one a partial response. These positive results support further clinical development of BMC128 by licensing partner Lishan Biotech.
Experimental gut bacteria cancer therapy shows early anti-tumor signal
Evogene (Nasdaq: EVGN) announced the successful completion of a Phase 1 clinical study of BMC128, a rationally designed live bacterial product, in combination with Nivolumab for patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities and showed preliminary anti-tumor activity, including stable disease in five patients and one partial response. The positive results support continued development and commercialization by licensing partner Lishan Biotech.
MUFG Securities EMEA plc Has $3.11 Million Position in General Motors Company $GM
MUFG Securities EMEA plc significantly increased its stake in General Motors (GM) by 109.9% in Q4, now holding 38,243 shares valued at $3.11 million. Wall Street analysts maintain a "Moderate Buy" rating for GM with an average price target of $95.65, despite recent insider sales and concerns over potential supplier strikes impacting truck production. The company recently reported strong Q1 earnings, beating analyst estimates, and announced a quarterly dividend of $0.18 per share.
Amazon's Ring sued over facial recognition feature, latest privacy concern for doorbell maker
Amazon's Ring unit is facing a class-action lawsuit filed by a Virginia resident, Charles Sigwalt, alleging privacy violations due to its "Familiar Faces" facial recognition feature. Sigwalt claims the feature collects and stores images of passersby without consent, seeking at least $5 million in damages. This lawsuit adds to a series of privacy controversies for Ring, including past settlements with the FTC over employee monitoring and concerns regarding partnerships with law enforcement.



